Biocon Biologics has partnered with Civica to improve access to and affordability of insulin aspart in the U.S. Biocon will supply the insu...

Biocon has launched Liraglutide, a drug for diabetes and obesity management, in the UK under the brand names Liraglutide Biocon and Biolide...

Biocon shares increased by 4.5% after the US FDA classified its Malaysian insulin facilities as Voluntary Action Indicated. This followed a...

Axis Securities and JM Financial both maintain 'Buy' ratings on Biocon, with target prices of Rs 370 and Rs 380, respectively. Biocon has a...

Eshwar Karra, CEO – Kotak Special Situations Fund at Kotak Investment Advisors said, We are delighted to partner with Biocon and this acqui...

The transaction with US-based Viatris required regulatory approvals from the Reserve Bank of India, Competition Commission of India and the...

The CBI has arrested Joint Drugs Controller S Eswara Reddy, Associate Vice President of Biocon Biologics L Praveen Kumar and three others i...

Out of $2 billion, $800 million will come through equity infusion from existing investors including parent Biocon and others such as Serum ...

“It will be a mix of debt, equity and of course IPO. It is going to be a very interesting business opportunity and a very comfortable aspec...

The country’s largest biopharmaceutical company’s net profits before exceptional items grew by 11% to Rs 188 crore in the quarter, it repor...

The regulator on Thursday restrained Shreehas P Tambe, senior Vice President of Biocon, from associating himself with any listed company an...

USFDA had conducted a pre-approval inspection of Biocon's subsidiary Biocon Sdn BHd's manufacturing facility in Malaysia for Insulin Glargi...